The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat individuals with mild cognitive impairment or mild dementia consistent with ...
Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance ... that is specific to the subcutaneous form. In a statement, Eisai and Biogen said ...
The VHA website states that veterans who request lecanemab must be over 65, sign a consent form, have been diagnosed ... VHA will be paying for the drug. Leqembi’s annual list price is $26,500.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback